Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rudolf E Schopf

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Pimecrolimus. NovartisRudolf E Schopf
Journal of the American Academy of Dermatology|June 14, 2002
Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximabRudolf E Schopf, Holger Aust, Jürgen Knop
The Journal of Investigative Dermatology|August 8, 2002
A highly decreased binding of cyclic adenosine monophosphate to protein kinase A in erythrocyte membranes is specific for active psoriasisRudolf E Schopf, Yvonne Langendorf, Roman E Benz, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 31, 2007
Treatment of psoriasis with fumaric acid esters (Fumaderm)Ulrich Mrowietz, Peter Altmeyer, Thomas Bieber, et al.
Therapeutic Advances in Neurological Disorders|January 11, 2020
PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disordersSinah Engel, Felix Luessi, Aneka Mueller, et al.
The Journal of Dermatological Treatment|June 9, 2025
Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO studyMatthias Augustin, Rudolf E Schopf, Sven R Quist, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2011
Human epidermal Langerhans cells replenish skin xenografts and are depleted by alloreactive T cells in vivoJulia Hemmerling, Joanna Wegner-Kops, Esther von Stebut, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Pimecrolimus. NovartisRudolf E Schopf
Journal of the American Academy of Dermatology|June 14, 2002
Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximabRudolf E Schopf, Holger Aust, Jürgen Knop
The Journal of Investigative Dermatology|August 8, 2002
A highly decreased binding of cyclic adenosine monophosphate to protein kinase A in erythrocyte membranes is specific for active psoriasisRudolf E Schopf, Yvonne Langendorf, Roman E Benz, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 31, 2007
Treatment of psoriasis with fumaric acid esters (Fumaderm)Ulrich Mrowietz, Peter Altmeyer, Thomas Bieber, et al.
Therapeutic Advances in Neurological Disorders|January 11, 2020
PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disordersSinah Engel, Felix Luessi, Aneka Mueller, et al.
The Journal of Dermatological Treatment|June 9, 2025
Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO studyMatthias Augustin, Rudolf E Schopf, Sven R Quist, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2011
Human epidermal Langerhans cells replenish skin xenografts and are depleted by alloreactive T cells in vivoJulia Hemmerling, Joanna Wegner-Kops, Esther von Stebut, et al.
Pageof 1